Tolerability of gemcitabine and carboplatin doublet therapy in cats with carcinomas

Journal of Veterinary Internal Medicine

Volumn 23, Issue 3, 2009, Pages 570-577

  Martinez Ruzafa, I ^b   Dominguez, P A ^a   Dervisis, N G ^a   Sarbu, L ^c   Newman, R G ^d   Cadile, C D ^e   Kitchell, B E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Upstate Veterinary Specialists   (United States)

^c VCA Specialty Center of Seattle   (United States)

^d Pittsburg Veterinary Specialty and Emergency Center   (United States)

^e Veterinary Medicine Specialists   (United States)

Author keywords

Chemotherapeutics; Chemotherapy; Drug interactions; Oncology treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

ADRENAL TUMOR; ANIMAL; ANIMAL DISEASE; ARTICLE; CARCINOMA; CAT; CAT DISEASE; CLINICAL TRIAL; DRUG COMBINATION; EXPERIMENTAL NEOPLASM; FEMALE; INTESTINE TUMOR; LIVER TUMOR; MALE;

ADRENAL GLAND NEOPLASMS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; CAT DISEASES; CATS; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; INTESTINAL NEOPLASMS; LIVER NEOPLASMS; MALE; MAMMARY NEOPLASMS, ANIMAL;

ANIMALIA;

EID: 67449094428     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2009.0279.x     Document Type: Article

References (36)

1. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:3-10.
2. Zatloukal P, Kanitz E, Magyar P, et al. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: The Central European Phase II study. Lung Cancer 1998;22:243-250.
3. Seidman AD. Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology (Williston Park) 2001;15:11-14.
4. Lund B, Hansen OP, Neijt JP, et al. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anticancer Drugs 1995;6(Suppl 6):61-62.
5. Nabhan C, Krett N, Gandhi V, et al. Gemcitabine in hematologic malignancies. Curr Opin Oncol 2001;13:514-521.
6. Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997;24:S7-2-S7-7.
7. Heinemann V, Schulz L, Issels RD, et al. Gemcitabine: A modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 1995;22:11-18.
8. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin Oncol 1997;24:S7-24-S27-28.
9. Kosarek CE, Kisseberth WC, Gallant SL, et al. Clinical evaluation of gemcitabine in dogs with spontaneously occurring malignancies. J Vet Intern Med 2005;19:81-86.
10. Turner AI, Hahn KA, Rusk A, et al. Single agent gemcitabine chemotherapy in dogs with spontaneously occurring lymphoma. J Vet Intern Med 2006;20:1384-1388.
11. LeBlanc AK, LaDue TA, Turrel JM, et al. Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: A veterinary radiation therapy oncology group pilot study. Vet Radiol Ultrasound 2004;45:466-470.
12. Jones PD, de Lorimier LP, Kitchell BE, et al. Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma. J Am Anim Hosp Assoc 2003;39:463-467.
13. Freise KJ, Martin-Jimenez T. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics. J Vet Pharmacol Ther 2006;29:137-145.
14. Freise KJ, Martin-Jimenez T. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. J Vet Pharmacol Ther 2006;29:147-152.
15. Reed E. Cisplatin, carboplatin, and oxaliplatin. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:332-343.
16. Johnson SW, O'Dwyer PJ. Cisplatin and its analogues. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:344-358.
17. Kisseberth WC, Vail DM, Yaissle J, et al. Phase I clinical evaluation of carboplatin in tumor-bearing cats: A Veterinary Cooperative Oncology Group study. J Vet Intern Med 2008;22:83-88.
18. Hahn KA, McEntee MF, Daniel GB, et al. Hematologic and systemic toxicoses associated with carboplatin administration in cats. Am J Vet Res 1997;58:677-679.
19. Theon AP, VanVechten MK, Madewell BR. Intratumoral administration of carboplatin for treatment of squamous cell carcinomas of the nasal plane in cats. Am J Vet Res 1996;57:205-210.
20. Dhaliwal RS, Johnson TO, Kitchell BE. Primary extraskeletal hepatic osteosarcoma in a cat. J Am Vet Med Assoc 2003;222: 340-342, 316.
21. Spugnini EP, Ruslander D, Bartolazzi A. Extraskeletal osteosarcoma in a cat. J Am Vet Med Assoc 2001;219:60-62, 49.
22. van Moorsel CJ, Pinedo HM, Veerman G, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and nonsmall-cell lung cancer cell lines. Br J Cancer 1999;80:981-990.
23. Crul M, van Waardenburg RC, Bocxe S, et al. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol 2003;65:275-282.
24. Peters GJ, Bergman AM, Ruiz van Haperen VW, et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995;22:72-79.
25. Bergman AM, Ruiz van Haperen VW, Veerman G, et al. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996;2:521-530.
26. Villella J, Marchetti D, Odunsi K, et al. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma. Gynecol Oncol 2004;95:539-545.
27. Rose PG, Mossbruger K, Fusco N, et al. Gemcitabine reverses cisplatin resistance: Demonstration of activity in platinum-and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 2003;88:17-21.
28. Bang S, Jeon TJ, Kim MH, et al. Phase II study of cisplatin combined with weekly gemcitabine in the treatment of patients with metastatic pancreatic carcinoma. Pancreatology 2006;6: 635-641.
29. Abratt RP, Hacking DJ, Goedhals L, et al. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma. Semin Oncol 1997;24:S8-18-S18-23.
30. Voigt W, Bulankin A, Muller T, et al. Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res 2000;6:2087-2093.
31. Xiros N, Papacostas P, Economopoulos T, et al. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: A phase II multicenter study by the Hellenic Cooperative Oncology Group. Ann Oncol 2005;16:773-779.
32. Boyce KL, Kitchell BE. Treatment of canine lymphoma with COPLA/LVP. J Am Anim Hosp Assoc 2000;36:395-403.
33. Mauldin GN, Matus RE, Patnaik AK, et al. Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats. J Vet Intern Med 1988;2:60-65.
34. Ogilvie GK, Moore AS, Obradovich JE, et al. Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors. J Am Vet Med Assoc 1993;202: 1839-1844.
35. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol 1988;4:121-141.
36. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-3952.